UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

		FORM 8-K/A			
	CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934				
		Date of Report (Date of earliest event reported): September 6, 2022		r 6, 2022	
Delaware (State or other jurisdiction of incorporation)		HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter) 001-38993 (Commission File Number)		45-3337483 (IRS Employer Identification No.)	
		(Regist	(801) 708-6800 rant's telephone number, including area code)		
		(Former na	Not Applicable me or former address, if changed since last repor	t)	
_		=	to simultaneously satisfy the filing obligation of	the registra	nt under any of the following provisions:
	•	rsuant to Rule 425 under the Securities Act (17 CFR 230.425) to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
	• •	-	b) under the Exchange Act (17 CFR 240.14d-2(b))	
	Title of each class	Securities	registered pursuant to Section 12(b) of the Act: Trading Symbol(s)	Name o	of exchange on which registered
	Common Stock, par value \$0.00)1 per share	HCAT		Nasdaq Global Select Market
of the Emo	he Securities Exchange Act of 1934 ((§24 erging growth company □	10.12b-2 of this chapter check mark if the regis	strant has elected not to use the extended transition		

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This filing amends Item 5.02 of the Current Report on Form 8-K filed by Health Catalyst, Inc. (the "Company") with the Securities and Exchange Commission on September 7, 2022 (the "Prior 8-K"). As previously reported in the Prior 8-K, J. Patrick Nelli transitioned from his role as President of the Company to Senior Advisor as of September 30, 2022. On December 30, 2022, Mr. Nelli and the Company entered into a separation agreement (the "Separation Agreement") in connection with Mr. Nelli's departure from the Company, effective December 31, 2022. In exchange for Mr. Nelli's general release of claims and compliance with the restrictive covenants contained in his employment agreement with the Company, Mr. Nelli will receive the following consideration: (i) a lump sum cash payment of \$258,740.46 within thirty (30) days, which represents 9 months' base salary for Mr. Nelli and an amount equal to COBRA premiums for 9 months, (ii) certain equity awards previously granted to Mr. Nelli will be accelerated under the terms of the Separation Agreement, resulting in the vesting of 72,096 restricted stock units of the Company, and (iii) the one-year additional extension of the expiration date for certain previously vested options to purchase common stock of the Company held by Mr. Nelli. This arrangement is also in recognition of Mr. Nelli's extraordinary contributions to the Company over the past nine years, for which the Company is deeply grateful.

The foregoing description of the terms of the Separation Agreement is qualified in its entirety by reference to the Separation Agreement, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2022.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 6, 2023

By: ______/s/ Bryan Hunt

Bryan Hunt

Chief Financial Officer

HEALTH CATALYST, INC.